Population pharmacokinetics and its role in anti-tuberculosis drug development and optimization of treatment

Current Pharmaceutical Design

Volumn 17, Issue 27, 2011, Pages 2889-2899

  Egelund, Eric Free ^a   Barth, Aline Bergesch ^a   Peloquin, Charles Arthur ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Ethambutol and fluoroquinolones; Population pharmacokinetics; Pyrazinamide; Rifabutin; Rifampin; Rifapentine

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; LOPINAVIR; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

AREA UNDER THE CURVE; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG HALF LIFE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS;

EID: 80053540908     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797470246     Document Type: Review

References (65)

1. Herzog H. History of tuberculosis. Respiration 1998; 65(1): 5-15.
2. WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health 2010, 18(4): 237.
3. UNAIDS: Frequently asked questions about tuberculosis and HIV.; 2006.
4. Concordet DL, F., Ané C.: Population PK/PD Analysis. In Encylopedia of Biopharmaceutical Statistics. 2nd edition. Edited by Chow S-C. New York: Marcel Dekker, Inc; 2004.
5. Shen DL, Zaizai: Population Pharmacokinetics Studies with Nonlinear Mixed Effects Modeling. In SAS Global Forum 2007. Orlando, Florida; 2007.
6. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004; 38(10): 1702-6.
7. Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984; 15(1-2): 153-71.
8. Jelliffe R, Schumitzky A, Van Guilder M. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. Ther Drug Monit 2000; 22(3): 354-65.
9. Neely M, Jelliffe R. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician. J Clin Pharmacol 2010; 50(7): 842-47.
10. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitropharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190(9): 1642-51.
11. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. San Antonio: Springer; 2010.
12. Guidance for industry on Population Pharmacokinetics; availability. Food and Drug Administration, HHS. Notice. Fed Regist 1999; 64(27): 6663-4.
13. Arthur J. Atkinson Jr. CED, Robert Dedrick, Charles V. Grudzinskas, Sanford P. Markey (Ed.): Principles of Clinical Pharmacology. San Diego: Academic Press; 2001.
14. Bustad A, Terziivanov D, Leary R, Port R, Schumitzky A, Jelliffe R. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006; 45(4): 365-83.
15. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9(1): E60-83.
16. Proost JH, Eleveld DJ. Parametric and nonparametric population methods. Clin Pharmacokinet 2006; 45(8): 851-852; author reply 852-4.
17. Nuermberger E, Grosset J: Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004; 23(4): 243-55.
18. Goutelle S, Bourguignon L, Maire PH, Van Guilder M, Conte JE, Jr., Jelliffe RW. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009; 53(7): 2974-81.
19. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41(12): 2670-79.
20. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51(11): 3781-8.
21. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokineticspharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47(7): 2118-24.
22. Wilkins JJ, Savic RM, Karlsson MO, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother 2008; 52(6): 2138-48.
23. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2007.
24. Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003; 17(18): 2615-22.
25. Burman WJ: Issues in the management of HIV-related tuberculosis. Clin Chest Med 2005; 26(2): 283-294, vi-vii.
26. Elsherbiny D, Ren Y, McIlleron H, Maartens G, Simonsson US. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. Eur J Clin Pharmacol 2010; 66(10): 1017-23.
27. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48(5): 1553-60.
28. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Edited by Services HaH 2011: 1-166.
29. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996; 22 Suppl 1: S15-21; discussion S21-12.
30. Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989; 33(8): 1237-41.
31. Gatti G, Papa P, Torre D, et al. Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998; 42(8): 2017-23.
32. Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009; 49(9): 1305-11.
33. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40(10): 1481-91.
34. Priftin package insert. In Aventis Pharmaceuticals. Midrand, South Africa: Aventis Pharmaceuticals; 2000.
35. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIVnegative patients: a randomised clinical trial. Lancet 2002; 360(9332): 528-34.
36. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353(9167): 1843-7.
37. Mitchison DA: Development of rifapentine: the way ahead. Int J Tuberc Lung Dis 1998; 2(8): 612-15.
38. Daniel N, Lounis N, Ji B, et al. Antituberculosis activity of onceweekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. Am J Respir Crit Care Med 2000; 161(5): 1572-7.
39. Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004; 169(11): 1191-7.
40. Langdon G, Wilkins J, McFadyen L, McIlleron H, Smith P, Simonsson US. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. Antimicrob Agents Chemother 2005; 49(11): 4429-36.
41. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3(2): 108-27.
42. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 1995; 275(2): 1011-8.
43. Iseman MD. In A Clinician's Guide to Tuberculosis. Philidelphia: Lippincott Williams & Wilkins; 2000: 277-80.
44. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007; 51(7): 2329-36.
45. Jeena PM, Bishai WR, Pasipanodya JG, Gumbo T. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob Agents Chemother 2011; 55(2): 539-45.
46. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005; 49(5): 1733-8.
47. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol 2011.
48. Peloquin CA. Pharmacology of the antimycobacterial drugs. Med Clin North Am 1993; 77(6): 1253-62.
49. Davies P (Ed.): Clinical Tuberculosis. London: Arnold Publishers; 2003.
50. Zhu M, Burman WJ, Starke JR, et al. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis 2004; 8(11): 1360-7.
51. Snow TJFaGA (Ed.): Biochemistry and Molecular Biology of Antimicrobial Drug Action. New York: Springer Science+Business Media, Inc.; 2005.
52. Singh P, Mishra AK, Malonia SK, et al. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. J Commun Dis 2006; 38(3): 288-98.
53. Gumbo T, Dona CS, Meek C, Leff R. Pharmacokineticspharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53(8): 3197-204.
54. Pasipanodya JG, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother 2010; 54(7): 2847-54.
55. Zhu M, Starke JR, Burman WJ, et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 2002; 22(6): 686-95.
56. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 2006; 62(9): 727-35.
57. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998; 2(4): 265-71.
58. Chen TC, Lu PL, Lin CY, Lin WR, Chen YH. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 2011; 15(3): e211-16.
59. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52(3): 852-7.
60. Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51(2): 576-82.
61. Weiner M, Burman W, Luo CC, et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007; 51(8): 2861-6.
62. Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007; 45(8): 1001-7.
63. Rubino CM, Capparelli EV, Bradley JS, et al. Population pharmacokinetic model for gatifloxacin in pediatric patients. Antimicrob Agents Chemother 2007; 51(4): 1246-52.
64. Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29(12): 1468-81.
65. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62(15): 2169-83.